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This prospective multicentre phase II study characterises the toxicity and activity of first-line capecitabine and oxaliplatin combination
therapy (CAPOX) in advanced biliary system adenocarcinomas. Patients received oxaliplatin (130mgm
 2, day 1) plus capecitabine
(1000mgm
 2 b.i.d., days 1–14) every 3 weeks. Patients were stratified prospectively into two groups based on location of the
primary (gallbladder carcinoma (GBC) or extrahepatic cholangiocarcinoma (ECC) versus intrahepatic mass-forming type
cholangiocarcinoma (ICC)). Sixty-five patients were evaluable. The response rate in 47 patients with GBC/ECC was 27% (4%
complete responses), and in 23 patients (49%) stable disease (SD) was encountered. In 18 patients with ICC, we observed no
objective responses, but 6 patients (33%) had SD. Median survival was 12.8 months (95% CI, 10.0–15.6) for patients with GBC or
ECC (GBC: 8.2 months; 95% CI, 4.3–11.7; ECC: 16.8 months; 95% CI, 12.7–20.5), and 5.2 months (95% CI, 0.6–9.8) for ICC
patients. In both cohorts, therapy was well tolerated. The most common grade 3–4 toxicity was peripheral sensory neuropathy (11
patients). Our data suggest that the CAPOX regimen is a well-tolerated and active treatment option for advanced ECC and GBC but
might produce poorer results for ICC.
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Biliary system adenocarcinomas include clearly defined gallbladder
carcinomas (GBC) as well as two main types of cholangiocarcinomas
(CCCs): an infiltrative ductal type involving extrahepatic (ECC)
and in some cases intrahepatic bile ducts, and an intrahepatic
mass-forming type (ICC). These morphologically distinct
presentations have been shown not only to differ at the molecular
level, but also appear to be distinct in clinical behaviour and with
regard to response to cytotoxic drugs (Jarnagin et al, 2006).
To date, complete surgical resection provides the only curative
treatment option in the early stages of these neoplasms irrespective
of their origin within the biliary system. However, less than one-
third of CCCs are resectable, and patients presenting with UICC
stage IV GBC or with unresectable CCC treated only by best
supportive care have a poor prognosis with a median survival time
of less than 6 months (Parker et al, 1996; Pitt et al, 1997; Jarnagin
et al, 2001; Weber et al, 2002).
At present, there is no established palliative standard of care for
GBC and CCC, and the cytotoxic agents most extensively studied,
as single agents are 5-fluorouracil (5-FU), gemcitabine, cape-
citabine, mitomycin C, cisplatin, doxorubicin, and methotrexate,
resulting in partial responses (PRs) in about 10–20% of selected
patients (Hejna et al, 1998; Penz et al, 2001). However, some
phase-II trials indicate that the use of combination therapies with
newer agents may boost response rates to 26% and higher (Knox
et al, 2005; Harder et al, 2006).
To date, the only randomised trial for advanced biliary
carcinomas, including an observational control arm, has shown
an improvement of overall survival (OS) (6.5 versus 2.5 months) as
well as quality of life, assessing a regimen of 5-FU plus leucovorin
with or without etoposid, as compared to best supportive care
(Glimelius et al, 1996).
In this setting, other treatment modalities, such as photo-
dynamic therapy, have yielded preliminary beneficial results only
for patients with ECC due to locoregional tumour control but not
for those with metastatic disease (Ortner et al, 1998). A survival
benefit of photodynamic therapy over best supportive care has
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sonly been demonstrated for patients not amenable to conventional
stenting procedures (Ortner et al, 2003); therefore, its value
relative to conventional stenting procedures remains unclear.
Recently performed targeted therapy approaches with the Her/
2-neu and/or EGFR inhibitors lapatinib or erlotinib have shown
no or only modest activity (0 and 8% responses, respectively) in
advanced biliary system adenocarcinomas (Philip et al, 2006;
Ramanathan et al, 2006).
Thus, a rational basis for the treatment of advanced stages of
biliary system adenocarcinomas might only be provided by
cytotoxic treatment alone or in the context of a multimodality
therapy strategy, including chemotherapy.
Oxaliplatin (l-OHP), an alkylating diaminocyclohexane
platinum derivate, has been noted to display a marked cytotoxic
synergism in combination with fluoropyrimidines against a variety
of solid human tumour cells (Raymond et al, 1997).
Therefore, we recently have conducted a prospective phase II
study of two-weekly oxaliplatin plus high-dose 5-FU/folinic acid
in biliary system adenocarcinomas. The disease control rate
(responses and stable disease (SD)) was 56%, and the median OS
was 9.5 months (Nehls et al, 2001). To improve efficacy and to
offer a more convenient treatment option for patients by reducing
clinical visits and avoiding indwelling devices, we prospectively
investigated the activity and toxicity profile of three-weekly
intravenous oxaliplatin plus oral capecitabine (CAPOX) in two
stratified cohorts with either advanced GBC and ECC (group A) or
advanced ICC (group B).
PATIENTS AND METHODS
Eligibility criteria
This prospective, four-institutional study, which was officially
accredited by the Arbeitsgemeinschaft Internistische Onkologie
(AIO), enrolled 66 consecutive patients with the diagnosis of
biliary system adenocarcinoma between February 2002 and
January 2004.
Criteria for inclusion were histologically or cytologically
confirmed adenocarcinomas of the gallbladder or the intrahepatic
or extrahepatic biliary tract not amenable to curative surgical
treatment strategies according to an Interdisciplinary Board of
oncologists, surgeons, radiologists, and radiooncologists.
Other criteria for inclusion were at least one bidimensionally
measurable lesion (ascites and pleural effusions were not
considered measurable), Eastern Cooperative Oncology Group
(ECOG) performance status (PS) p2, age 18–75 years, adequate
bone marrow (leucocyte count X3.5 10
9 per l, platelet count
X100 10
9 per l), renal (creatinine-clearance X60mlmin
 1) and
hepatic function (total serum bilirubin o2.0mg per 100ml,
transaminases o2  the upper limit of normal), and no prior
cytotoxic treatment.
The trial protocol was approved by the local ethics review
boards of all participating Hospitals, and written consent was
obtained from all patients before any study-specific procedures.
Patient evaluation
Before entry onto study, all patients underwent a full medical
history, physical examination, PS, and laboratory evaluation. In
addition, baseline evaluation included electrocardiograms, chest
X-rays, abdominal ultrasounds, and computed tomography scans
(alternatively magnetic resonance imaging scans) of the abdomen.
Further imaging investigations were added if clinically indicated or
for disease assessment.
Objective tumour evaluation for response was performed
according to World Health Organization (WHO) standard criteria
(World Health Organization, 1979). A complete response (CR) was
defined as disappearance of all measurable or evaluable disease
with the absence of any new lesions for at least 4 weeks. A PR was
defined as a 450% reduction in the sum of the products of the
largest perpendicular diameters of all measurable lesions with the
absence of any new lesions for at least 4 weeks. Stable disease
was defined as a reduction of o50% or an increase of o25% of
measurable lesions according to the previous method, with the
absence of any new lesions. Progressive disease (PD) was
characterised by an increase of 425% of measurable lesions
according to the previous method or the appearance of new
lesions. A baseline radiographic tumour evaluation was performed
within 2 weeks before treatment started and repeated after two
cycles, and again after every further three cycles by the same
imaging method that was used for baseline measurement.
Additional evaluations were performed if PD was suspected.
Clinical response assessment was determined separately for
patients with either GBC/ECC or ICC, because these two distinct
presentations have been supposed to differ substantially from
each other according to clinical behaviour (hilar CCCs (Klatskin
tumours) have been categorised as ECC). Accordingly, patients
were entered prospectively into two nonrandomised parallel
groups based on location of the primary (GBC/ECC versus ICC)
in order to evaluate the outcome more accurately. Moreover,
subgroup analysis of hilar versus distal CCCs was performed.
Toxicity was assessed using the National Cancer Institute
Common Toxicity Criteria (NCI-CTC), except for neurologic
toxicity, that was graded according to Le ´vis scale.
Treatment schedule
Patients received, on outpatient basis, the CAPOX regimen as
reported previously (Andre ´ et al, 1999). In brief, capecitabine
1000mg per m
2 per dose was administered orally twice a day on
days 1–14, followed by a 7-day treatment-free period. Oxaliplatin,
130mgm
 2, was administered as a 2-h infusion on day 1, in a
3-week cycle. All patients received, as concomitant antiemetic
prophylaxis, a 5-HT 3 antagonist intravenously prior to each
oxaliplatin dose.
Treatment was terminated in the case of disease progression,
intolerable side effects, or patient’s choice to discontinue the
therapy.
To prevent oxaliplatin-induced neurotoxicity, all patients
received carbamazepine (initially 100mg b.i.d. to achieve a
serum-level of 3–6mgl
 1) according to the preliminary results
of a pilot study (Lersch et al, 2002).
Toxicity and dosage modification guidelines
The toxicities were graded according to NCI-CTC (version 2).
Capecitabine doses should be interrupted in cases of grade 2 or
higher events (except alopecia) and treatment should be delayed
until complete recovery or until the adverse event improved to
grade 0 or 1. Capecitabine was decreased by 25% in subsequent
cycles at the first occurrence of a grade 2 or 3 toxicity, and it was
reduced by 50% at the second occurrence of a given grade 2 or
grade 3 toxicity or at the first occurrence of a grade 4 event.
Treatment with capecitabine was permanently stopped if, despite
dose reduction, a given toxicity occurred for the third time at
grade 2 or grade 3, or a second time at grade 4.
Oxaliplatin was reduced by 25% in subsequent cycles for grade 3
or 4 neutropenia or thrombocytopenia, grade 3 diarrhoea or
mucositis, any other drug-related grade 3 toxicity or painful
paresthesias lasting 8–14 days (without functional impairment)
(grade 2 according to Le ´vis scale), whereas oxaliplatin was
diminished by 50% if persistent (414 days) paresthesias
(without functional impairment) emerged (grade 3). Oxaliplatin
was stopped if a beginning functional impairment occurred
(grade 4).
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treatment was delayed for more than 3 weeks, patients were
removed from the study.
Statistical considerations
The main objective of the study was the response rate (CR and PR)
according to WHO criteria. Both cohorts (groups A and B) were
analysed separately according to Simon’s two-stage design (Simon,
1989). If two or less CR or PR were noted in the first 18 patients
of a group, accrual would stop in this cohort, otherwise it was
planned to accrue at least 43 patients in this group to determine
outcome more accurately. Assuming that about 5% of patients
could not be evaluable, the accrual was planned to continue to a
total of 47 patients for the second step of a group. The significance
level was 5% and the power was 80%.
Secondary objectives were safety, OS, and time to progression
(TTP). Overall survival or TTP were calculated both from the
initiation of chemotherapy until death and from the date
of objectively measured disease progression till the occurrence of
death from any cause. The cutoff was 30 April 2007. Statistical
analysis was performed using SPSS for Windows 11.5 (SPSS Inc.,
Chicago, IL, USA). Median OS and TTP were estimated according
to the Kaplan–Meier method (Kaplan and Maier, 1959).
RESULTS
Patient characteristics
A total of 66 patients (27 men and 39 women) were enrolled onto
this multicenter trial at the University Hospitals of Berlin,
Frankfurt, Mannheim and Tu ¨bingen, Germany, and 65 patients
were evaluable for efficacy and safety. One patient was retro-
spectively found to have a diagnosis of pancreatic adenocarcinoma
and has been disclosed from the study. Patient characteristics are
detailed in Table 1.
The median age of the study population was 61 years (range,
28–74). Twenty-seven, 20, and 18 had adenocarcinoma of the
gallbladder, ECC, or ICC, respectively.
In group A (GBC or ECC), three patients (6%) had locoregional
advanced disease. Forty-four patients (94%) had metastatic
disease. Sixteen patients had one metastatic site (34%), and 28
patients (60%) had two affected sites and more. Liver involvement
was noted in 39 patients (83%). In group B (ICC), four patients
(22%) had one metastatic site, and 14 patients (78%) had two
affected sites and more (Table 1).
In groups A and B, 21 and 5 patients, respectively, experienced
disease recurrence or metastatic spread to distant organs after they
had undergone curatively intended surgery previously.
Efficacy
In group A, 2 of the 47 patients (4%) achieved a complete
remission, 11 patients (23%) experienced a partial remission, and
SD was noted in 23 patients (49%). Accordingly, the overall disease
control rate (CR, PR, or SD) on 47 patients with GBC or ECC was
77%, and PD was found in 11 patients (23%). From initiation of
chemotherapy, actuarial estimation of the median TTP and median
OS were 6.5 months (95% CI, 5.3–7.7 months), and 12.8 months
(95% CI, 10.0–15.6 months), respectively. At the cutoff of the
study, two patients of group A were still alive.
In group B, no CR or PR was observed in 18 patients with ICC,
but six patients (33%) had SD, and 12 patients (68%) experienced
PD. Median TTP and OS were 2.2 months (95% CI, 1.4–3.0
months) and 5.2 months (95% CI, 0.6–9.8 months), respectively.
At the cutoff of the study, all patients of group B have died.
Subgroup analysis for efficacy
The results of the response rates for patients with GBC versus ECC
are detailed in Table 2.
Furthermore, survival analysis for patients with GBC versus
ECC revealed markedly differences on both TTP (Figure 1A;
Kaplan–Meier curves for TTP) and OS (Figure 1B; Kaplan–Meier
curves for OS). Thus, TTP or OS in GBC and ECC were 4.7 months
(95% CI, 3.7–5.7) and 11.3 months (95% CI, 10.6–12.0),
respectively, or 8.0 months (95% CI, 4.3–11.7) and 16.6 months
(95% CI, 12.7–20.5), respectively. Subgroup analysis of patients
with hilar versus distal CCC showed no significant differences on
TTP or OS. Thus, TTP or OS in hilar and distal CCC were 6.5
months (95% CI, 5.1–7.9) and 11.3 months (95% CI, 10.4–12.2),
respectively, or 20.1 months (95% CI, 12.2–28) and 15.3 months
(95% CI, 8.7–21.9), respectively (log-rank test, P¼0.85, or
P¼0.51).
Subgroup analysis of patients from groups A and B revealed that
TTP or OS was worst for patients with ICC compared to patients
with ECC or GBC (log-rank test; P¼0.01, or P¼0.03, respectively)
(Figure 1A and B).
Table 1 Patient characteristics by treatment group and site of the
primary
Group A
Group B
Characteristic Gallbladder
Extrahepatic
bile duct
Intrahepatic
bile duct
(mass-forming-type)
No. of patients 27 20 18
Age (years)
Median 61 66 52
Range 49–73 49–74 28–74
Sex (%)
Male 9 (33) 10 (50) 8 (44)
Female 18 (67) 10 (50) 10 (56)
PS, ECOG (%)
0 8 (30) 7 (35) 7 (39)
1 15 (55) 11 (55) 9 (50)
2 4 (15) 2 (10) 2 (11)
Sites of disease (%)
Locoregional 0 (0) 3 (15) 0 (0)
Liver 25 (93) 14 (70) 18 (100)
Lymph node 14 (52) 5 (25) 12 (67)
Lung 2 (7) 2 (10) 6 (33)
Peritoneum 1 (4) 1 (5) 0 (0)
Other 6 (22) 7 (35) 2 (11)
No. of metastatic sites (%)
1 10 (37) 6 (30) 4 (22)
X2 17 (63) 11 (70) 14 (78)
Prior surgery (%)
Yes 12 (44) 9 (45) 5 (28)
No 15 (56) 11 (55) 13 (72)
CEA elevated (%)
Yes 6 (22) 6 (30) 7 (39)
No 21 (78) 13 (65) 9 (50)
Not done 0 (0) 1 (5) 2 (11)
CA 19-9 elevated (%)
Yes 19 (70) 16 (80) 10 (56)
No 8 (30) 4 (20) 6 (33)
Not done 0 (0) 0 (0) 2 (11)
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All 65 patients were evaluable for toxic effects. A total of 367
courses of treatment have been administered (median, five courses
per patient; range, 1–17). The median cumulative doses for
oxaliplatin and capecitabine were 560mgm
 2 (range, 130–1.945)
and 8.500mgm
 2 (range, 2.000–30.500) corresponding to a
relative dose intensity of 86% for oxaliplatin and 85% for
capecitabine, respectively. In 46.2% of the patients, at least one
cycle of treatment was delayed due to oxaliplatin and/or
capecitabine-related side effects resulting in dose reductions for
oxaliplatin and capecitabin in 30.8 and 46.2% of the patients,
respectively. The recorded toxicities are summarised in Table 3.
The National Cancer Institute Common Toxicity Criteria grade 4
thrombocytopenia or febrile leukopenia was observed in one
patient each (2% of patients, respectively). Two patients (3%)
experienced grade 4 infection and a thrombembolic event grade 4
was reported in a single patient (2%). Grade 3 adverse events were
thrombocytopenia (9% of patients), nausea/vomiting (6%),
diarrhoea (5%), and hand–foot syndrome (5%). We observed no
line infections. The most common toxicity was peripheral
neuropathy observed in 54 of the 65 patients (83%). However,
grade 3 or 4 peripheral sensory neuropathy was encountered only
in 11 of the patients (17%) and 11% of courses (Table 4).
In two patients, study medication has been stopped due to
oxaliplatin-related allergic reactions occurring in cycles 1 and 6.
Generalised rash and fever have been recovered completely.
In one patient with ICC, chemotherapy was stopped after the
first treatment cycle due to progression-related cholangiosepsis
not amenable to stenting procedures. Despite treatment with
antibiotics, he died from septic shock.
Another patient with a history of long-standing insulin-
dependent diabetes mellitus died due to a cerebral ischaemic
insult after the first treatment cycle. This event has been
considered unlikely related to study treatment, but a causal
relation with the study medication cannot be excluded entirely.
Second-line treatment
Thirty-three patients (51%) underwent second-line chemotherapy
after treatment with the CapOx regimen failed (31, gemcitabine
monotherapy; 1, gemcitabine plus capecitabine; 1, mitomycin C
plus capecitabine). None of the patients achieved a PR or a CR
after second-line therapy.
DISCUSSION
Although there is no standard of care in advanced biliary system
adenocarcinoma, palliative chemotherapy to date remains the
primary therapeutic approach. Nevertheless, the search continues
for an appropriate cytotoxic treatment protocol for biliary tract
carcinoma. Moreover, it remains unclear if patients with GBC or
ECC may respond similarly to cytotoxic treatment as those with
ICC.
In the present prospective phase II trial, stratified prospectively
into two groups based on location of the primary (GBC or ECC
versus ICC), a response rate of 27% was achieved in 47 patients
with GBC or ECC (group A) (including 4% complete remissions)
adding to a disease-control rate (responses and SD) of 77%.
Moreover, response rates were comparable for patients with ECC
and GBC (30 and 25%).
In patients with ICC, SD was found in 33% of 18 cases, whereas
no objective tumour response could be detected in this subgroup.
Our data show that the CAPOX regimen may be active,
particularly in the subset of ECC and GBC, although it has only
modest activity in ICC.
This agrees with data from a recent trial using gemcitabine
combined with platinum-based cytotoxic treatment in 42 patients
with biliary system adenocarcinomas, which also demonstrated
both comparable response rates for patients with ECC and GBC
and a marked difference in response rates between GBC and ECC
versus ICC (40 and 43 versus 7%, respectively) (Table 5) (Harder
et al, 2006). The relatively higher response rates in the latter study
as compared to our data may reflect the use of a different
evaluation system (RECIST versus WHO criteria). In addition,
accumulating data suggest that GBC in comparison to ICC
responds noticeably better to various cytotoxic protocols (Table 5)
(Kim et al, 2003; Andre ´ et al, 2004; Patt et al, 2004; Alberts et al,
2005). These differences may reflect site-related distinct biologic
features (Jarnagin et al, 2006).
Of note, only in studies evaluating ICC and ECC as one entity,
classified as CCC, no obvious differences in response rates have
been found between CCC and GBC. It may be hypothesised that the
majority of responders in these studies were patients with ECC
(Table 5) (Knox et al, 2005; Verderame et al, 2006). In this context,
it should be emphasised that Klatskin tumours are misclassified as
ICC in a substantial number of cases (Welzel et al, 2006).
In our series, it was most striking that median OS for patients
with ECC was about twice as long than for patients with GBC (16.8
versus 8.1 months). Although the comparison of results of non-
randomised phase II trials regarding survival may be inconclusive,
that is, due to patient selection bias, our observation of an OS of
8.1 months for GBC was in good accordance with other phase II
trials using fluoropyrimidin-based therapies, platin-analogues, or
gemcitabine-based schedules (Table 5). A possible explanation for
a shorter survival for GBC compared to ECC may be the more
aggressive natural course of GBC, and that patients with ECC
might also benefit from local treatment (i.e., stenting procedures).
Conversely, one study found very long median survival times for
GBC (16 months) using a combination chemotherapy of oxaliplatin
Table 2 Best response to treatment
Group A
Extrahepatic bile duct carcinoma (n¼20)
Outcome
Gallbladder
carcinoma (n¼27)
Hilar
(n¼6)
Distal
(n¼14)
No. of patients (%)
Hilar and
distal (n¼20)
Group B
Intrahepatic bile duct
carcinoma (n¼18)
CR 1 (4) 0 (0) 1 (7) 1 (5) —
PR 7 (26) 2 (33) 2 (14) 4 (20) —
SD 9 (33) 3 (50) 11 (79) 14 (70) 6 (33)
PD 10 (37) 1 (17) 0 (0) 1 (5) 12 (67)
Disease control rate (CR or PR or SD) 36 (77) 6 (33)
Abbreviations: CR¼complete remission; PD¼progressive disease; PR¼partial remission; SD¼stable disease.
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using this combination protocol could not reproduce this result,
possibly due to differences in patient selection, inclusion criteria,
and/or applications of the drugs (Harder et al, 2006; Verderame
et al, 2006).
Therefore, randomised trials are warranted in biliary system
adenocarcinomas, stratified according to the three entities, GBC,
ICC, and ECC, to draw definitive conclusions about differences in
response rates and survival.
Fifty-one percent of our patients received second-line treatment,
but no complete or partial responses were seen in this setting.
Accordingly, an influence of second-line treatment on outcome
seems to be inferior.
The toxicity profile of the CAPOX regimen was generally
favourable. Gastrointestinal grade 3/4 toxicities were nausea/
vomiting and diarrhoea, each of which affected four patients
(6%) including grade 4 diarrhoea in only one patient (2%)
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Figure 1 The Kaplan–Meier curves of (A) TTP and (B) OS.
Table 3 Toxicity in any cycle (worst per patient) (both patient series
(groups A and B), n¼65)
Grade 2 Grade 3 Grade 4
No. of
patients %
No. of
patients %
No. of
patients %
Neutropenia 9 14 0 0 1 2
Febrile neutropenia 0 0 0 0 1 2
Thrombocytopenia 13 20 6 9 1 2
Anemia 12 18 0 0 0 0
Nausea/vomiting 19 29 4 6 0 0
Diarrhoea 12 18 3 5 1 2
Mucositis 1 2 0 0 0 0
Hand–foot syndrome 6 9 3 5 NA NA
Infection 10 15 0 0 2 3
Thrombembolic
events
00 001 2
Abbreviation: NA¼not applicable.
Table 5 Summary of phase II trials of biliary system adenocarcinoma (trials selected differ between GBC, ECC, and/or ICC)
No. of patients RR (%) Median survival (months)
Author (year) Regimen Metastatic disease % Total GBC ECC ICC GBC ECC ICC
Andre ´ et al (2004) Gemcitabine Oxaliplatin 94 31
w 11 (54) 4 (25) 16 (21) 16 NA 14.5
Kim et al (2003) Capecitabine Cisplatin 67 38* 19 (32) 9 (11) 14 (14) 9.1
Patt et al (2004) Capecitabine NA 26
w 8 (50) 18 (6) 9.9 8.1
Knox et al (2005) Gemcitabine Capecitabine 89 42* 22 (28) 23 (34) 6.6 19
Alberts et al (2005) Gemcitabine 5-FU/LV 83 42* 14 (21) 9 (7) 19 7.2 9.9
Verderame et al (2006) Gemcitabine Oxaliplatin 67 24* 9 (44) 15 (53) 6.0 12.0
Harder et al (2006) Gemcitabine Oxaliplatin 90 31* 10 (40) 7 (43) 14 (7) NA 13.3 8.4
This study Capecitabine Oxaliplatin 95 65
w 27 (30) 20 (25) 18 (0) 8.2 16.8 5.2
Abbreviations: ECC¼extrahepatic cholangiocarcinoma; GBC¼gallbladder carcinoma; ICC¼intrahepatic mass-forming type cholangiocarcinoma; NA¼data not available;
RR¼response rate;
wResponse evaluation according to WHO (World Health Organization) criteria; *Response evaluation according to RECIST (Response evaluation in Solid
Tumors) criteria.
Table 4 Incidence of neurosensory symptoms according to Le ´vi ´s scale
a
(worst per patient) (both patient series, group A and B), n¼65
Paresthesia
a Grade 1 Grade 2 Grade 3 Grade 4
No of patients (%) 20 31 23 35 10 15 1 2
No of cycles (%) 53 14 48 13 39 11 1 0.3
aLe ´vi ´s scale: grade 1, paresthesias of moderate intensity lasting less than 7 days; grade
2, painful paresthesias lasting 8–14 days (without functional impairment); grade 3,
persistent (414 days) paresthesias (without functional impairment); grade 4,
beginning functional impairment.
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regimen for treatment of gastrointestinal tumours other than
biliary (Park et al, 2006). The most common grade 3/4
haematological event was thrombocytopenia (11% of patients),
including a grade 4 event in a single patient (2%). No bleeding
disorders have been seen.
In the current study, we observed grade 2 infection in 10
patients and grade 4 infection in 2 patients, respectively, causing
treatment delays in only 4% of the courses. In contrast, Harder
et al (2006) found treatment delays in 9% of cycles using a regimen
with gemcitabine combined with oxaliplatin. Of note, in four of
our patients, infection was based on occlusion of biliary stents, and
in eight patients, no such association was found. Furthermore, in
one patient with and in one patient without stent insertion,
cholangiosepsis occurred.
However, no line infections were observed. In contrast, in a
previous study on advanced biliary cancers using a schedule based
on protracted infusion of 5-FU, rates of central line infection and
venous thrombosis were 19 and 7% (Knox et al, 2004) indicating
the risks of implantable devices.
Two patients who were withdrawn from our study due to an
allergic reaction to oxaliplatin recovered fully. This oxaliplatin-
related toxicity, typically occurring after application of 7–12
treatment cycles, was estimated to affect about 2% of patients
(Tournigand et al, 1998). In addition, three patients (5%)
developed grade 3 hand–foot syndrome.
The main grade 3/4 toxic effect was peripheral sensory
neuropathy, which was noted in 11 patients (17%) (Table 4).
However, this oxaliplatin-related side effect was reported to be
completely reversible after omission of oxaliplatin in more than
80% of the patients within 8 months (Gamelin et al, 2002).
In conclusion, the CAPOX regimen has a favourable safety
profile and is more convenient than infusional regimens, avoiding
the need for indwelling devices and frequent hospital visits.
Finally, the prospective data presented here may open a triad
perspective on adenocarcinomas of the biliary system after
platinum-based cytotoxic treatment. First, response rates and
outcome seem worst for patients with ICC compared to patients
with ECC or GBC, indicating that tumour growth in these
neoplasms may reflect other biological mechanisms than in GBC
and/or ECC; Second, GBC may have an intermediate prognosis
with response rates very similar to ECC, whereas outcome might
be poorer. Third, ECC, including perihilar CCC, may have high
response rates and median survival times that clearly tend to
exceed those of GBC and ICC. To prove these hypotheses,
prospective randomised trials should be undertaken.
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